Organigram Advances Cannabis Product Portfolio with $1M Investment in Phylos

LOS ANGELES- Organigram Holdings Inc. has announced the completion of a partial third tranche investment of $1 million into Phylos Bioscience Inc., a U.S.-based cannabis genetics company. This investment is part of a broader strategy to diversify and enhance Organigram’s product offerings, particularly in the auto-flower and rare cannabinoid sectors, including high-potency THCV, CBG, CBC, and CBDV cultivars.

The funding will enable Organigram to expand its portfolio with 42 unique auto-flower seed varietals, set for delivery in two phases by early 2025. This initiative aims to meet consumer demand for distinctive cannabis products with varied aromas and flavors. Organigram, which holds exclusive rights in Canada to commercialize THCV derived from Phylos’ cultivars, is strengthening its market position by introducing unique products such as SHRED’ems gummies and pre-rolls featuring high THCV content.

The total investment in Phylos now stands at approximately $7 million, structured as a convertible loan with future equity conversion potential, contingent on cannabis legalization in the U.S. The completion of the investment is expected by March 2026, conditional on achieving specific milestones. This partnership underscores Organigram’s commitment to innovation and product differentiation in the competitive cannabis market.